In the wake of European price cuts, pharmaceutical companies fear not only a hit in their revenues, but a fresh surge in so-called "parallel exports"--estimated to account for a tenth of Europe's medicine trade--elsewhere across the E.U., undermining their margins in many larger and richer countries. Report